RT Journal Article SR Electronic T1 Three More Drugs Judged “Breakthroughs” JF Cancer Discovery JO CANCER DISCOVERY FD American Association for Cancer Research SP OF2 OP OF2 DO 10.1158/2159-8290.CD-NB2013-142 VO 3 IS 11 YR 2013 UL http://cancerdiscovery.aacrjournals.org/content/3/11/OF2.abstract AB The U.S. Food and Drug Administration has granted Breakthrough Therapy status to volasertib, entinostat, and alectinib, which are under development for the treatment of acute myeloid leukemia, estrogen receptor–positive breast cancer, and non–small cell lung cancer, respectively.